Roivant Sciences (ROIV)
Develops immunology medicines and delivery technologies through focused Vant subsidiaries.
Something off on this page? Send us feedback.
Develops medicines and delivery technologies through focused Vant subsidiaries, with retained programs in autoimmune and inflammatory disease plus Genevant's lipid-nanoparticle platform. With no commercial-stage product at the latest fiscal year-end, economics depend on clinical outcomes, regulatory approvals, ownership, licensing, and patent rights.
Develops medicines and drug-delivery technologies through focused subsidiaries called Vants, which operate like independent biotechnology companies while sharing a broader platform. The retained portfolio centers on Priovant’s brepocitinib, Immunovant’s IMVT-1402, Pulmovant’s mosliciguat, and Genevant’s lipid-nanoparticle technology and patent interests.
Clinical work is concentrated in autoimmune and inflammatory disease. The workforce is concentrated in the United States, while principal offices are listed in London, New York, and Basel.
No retained commercial-stage product was present at the latest fiscal year-end. Economics therefore depend on clinical outcomes, regulatory approvals, future commercialization, ownership and licensing terms, while Genevant also depends on patent rights, settlement allocation, and an appellate contingency.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | Stifel Nicolaus | Target | Target: — | Target: $51 |
| Sep 9, 2026 | Guggenheim | Reiterate | Rating: —Target: $36 | Target: $46 |
| Sep 9, 2026 | UBS | Target | Target: — | Target: $55 |
| Sep 8, 2026 | H.C. Wainwright | Target | Target: $41 | Target: $47 |
| Sep 8, 2026 | Jefferies | Reiterate | Rating: —Target: $30 | Target: $52 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.84B · Total debt $107.2M · Total assets $5.31B · Shareholders' equity $4.23B
- Revenue
- $1.4M
- Operating income
- −$366.0M
- Net income
- −$189.8M
No dividends on record.
| Institutions | 77.60% | 560.56M shares | |
|---|---|---|---|
| 518 holders · as of Jun 30, 2026 | |||
| Insiders | 27.62% | 199.54M shares | |
| 12 holders · as of Sep 18, 2026 | |||
| Adds to | 105.22% | ||
722.32M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 105.22%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dan OrenInsiderdirector | 13.68% | 98.84M | filed Apr 26, 2022 |
FMR LLCInstitution | 11.22% | 81.02M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.68% | 48.24M | as of Jun 30, 2026 |
Vivek Ramaswamy1Insider10 percent owner | 6.51% | 47.01M | filed Dec 15, 2025 |
Morgan StanleyInstitution | 5.90% | 42.59M | as of Jun 30, 2026 |
- Reported at 3.60% on May 6, 2026, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Meghan Fitzgerald | director | −5,112 | $39.74 |
| Sep 15, 2026 | Melissa B. Epperly | director | −4,938 | $39.74 |
| Sep 8, 2026 | Meghan Fitzgerald | director | −20,000 | $39.90 |
| Aug 28, 2026 | Eric Venker | officer: President & Immunovant CEO | −200,000 | $35.77 |
| Aug 21, 2026 | Mayukh Sukhatme | director, officer: President & CIO | −144,756 | $36.48 |
- argenx (ADR)
Commercial FcRn leader across core autoimmune indications
- Johnson & Johnson
Approved FcRn challenger with a broad autoantibody pipeline
- Pfizer
Late-stage dermatomyositis rival with a distinct immune target
- United Therapeutics
Commercial PH-ILD incumbent with two inhaled Tyvaso formulations
- Liquidia
Newer inhaled treprostinil entrant in the PH-ILD market
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Roivant Sciences | $38.33 | +0.29% | $28.17B | — | — | 3,739.6 | −33.6% |
| argenx (ADR) | $964.20 | +0.02% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Johnson & Johnson | $269.61 | +0.12% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Pfizer | $27.90 | −0.11% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| United Therapeutics | $498.22 | +0.11% | $20.93B | 17.7 | 19.2 | 6.6 | −1.9% |
| Liquidia | $68.64 | 0.00% | $5.91B | 48.5 | 15.4 | 13.1 | +1,842.7% |
| Median | 36.7 | 17.3 | 6.6 | +6.6% |